TY  - GEN
AU  - Buske,C
AU  - Hoster,E
AU  - Dreyling,M
AU  - Eimermacher,H
AU  - Wandt,H
AU  - Metzner,B
AU  - Fuchs,R
AU  - Bittenbring,J
AU  - Woermann,B
AU  - Hohloch,K
AU  - Hess,G
AU  - Ludwig,W-D
AU  - Schimke,J
AU  - Schmitz,S
AU  - Kneba,M
AU  - Reiser,M
AU  - Graeven,U
AU  - Klapper,W
AU  - Unterhalt,M
AU  - Hiddemann,W
TI  - The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
SN  - 1476-5551
PY  - 2009///0206
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Humans
KW  - Middle Aged
KW  - Prednisone
KW  - Remission Induction
KW  - Rituximab
KW  - Treatment Outcome
KW  - Vincristine
KW  - Waldenstrom Macroglobulinemia
KW  - drug therapy
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2008.261
ER  -